{"id":64126,"date":"2026-04-28T12:05:24","date_gmt":"2026-04-28T04:05:24","guid":{"rendered":"https:\/\/flcube.com\/?p=64126"},"modified":"2026-04-28T12:05:25","modified_gmt":"2026-04-28T04:05:25","slug":"thermo-fisher-scientific-to-divest-microbiology-business-to-astorg-for-1-075-billion-strategic-portfolio-optimization","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64126","title":{"rendered":"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization"},"content":{"rendered":"\n<p><strong>Thermo Fisher Scientific Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TMO:NYSE\">NYSE: TMO<\/a>) announced on April 27, 2026, that it has signed a definitive agreement to sell its <strong>microbiology business<\/strong> to <strong>Astorg<\/strong>, a leading pan-European private equity firm, for approximately <strong>USD 1.075 billion<\/strong> in total consideration.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure-amp-timeline\">Transaction Structure &amp; Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Buyer<\/strong><\/td><td>Astorg (pan-European private equity firm)<\/td><\/tr><tr><td><strong>Seller<\/strong><\/td><td>Thermo Fisher Scientific Inc. (NYSE: TMO)<\/td><\/tr><tr><td><strong>Total Consideration<\/strong><\/td><td>USD 1.075 billion<\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Cash + USD 50 million seller note<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>Second half of 2026<\/td><\/tr><tr><td><strong>Conditions<\/strong><\/td><td>Customary closing conditions and regulatory approvals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-profile-amp-financial-metrics\">Business Profile &amp; Financial Metrics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>2025 Revenue<\/strong><\/td><td>USD 645 million<\/td><\/tr><tr><td><strong>Business Segment<\/strong><\/td><td>Specialty Diagnostics (Thermo Fisher)<\/td><\/tr><tr><td><strong>Core Products<\/strong><\/td><td>Antimicrobial susceptibility testing solutions<\/td><\/tr><tr><td><strong>Additional Offerings<\/strong><\/td><td>Culture media solutions<\/td><\/tr><tr><td><strong>End Markets<\/strong><\/td><td>Clinical diagnostics, pharmaceutical testing, food safety testing<\/td><\/tr><tr><td><strong>Revenue Multiple<\/strong><\/td><td>~1.7x (based on 2025 revenue)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-thermo-fisher-scientific\">For Thermo Fisher Scientific:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Optimization<\/strong>: Focus on higher-growth, higher-margin businesses within life sciences and diagnostics<\/li>\n\n\n\n<li><strong>Capital Allocation<\/strong>: Redirect resources to strategic priorities including bioproduction, genetic sciences, and laboratory products<\/li>\n\n\n\n<li><strong>Operational Streamlining<\/strong>: Reduce complexity in Specialty Diagnostics segment<\/li>\n\n\n\n<li><strong>Shareholder Value<\/strong>: Unlock value through disciplined portfolio management<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-astorg\">For Astorg:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Investment<\/strong>: Acquire established microbiology business with strong market position<\/li>\n\n\n\n<li><strong>Growth Potential<\/strong>: Leverage expertise in healthcare investments to accelerate business expansion<\/li>\n\n\n\n<li><strong>Market Diversification<\/strong>: Access attractive end markets in clinical, pharma, and food safety testing<\/li>\n\n\n\n<li><strong>Operational Improvement<\/strong>: Apply private equity operational expertise to enhance performance<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-industry-dynamics\">Market Context &amp; Industry Dynamics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Microbiology Testing Market<\/strong>: Growing demand driven by antimicrobial resistance concerns, food safety regulations, and pharmaceutical quality control requirements<\/li>\n\n\n\n<li><strong>Consolidation Trend<\/strong>: Continued M&amp;A activity in life sciences tools and diagnostics sectors<\/li>\n\n\n\n<li><strong>Private Equity Interest<\/strong>: Strong appetite for healthcare assets with stable cash flows and defensive characteristics<\/li>\n\n\n\n<li><strong>Strategic Focus<\/strong>: Large life science companies increasingly focusing on core competencies and divesting non-strategic assets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-forward-outlook\">Financial Impact &amp; Forward Outlook<\/h2>\n\n\n\n<p>The transaction represents a strategic divestiture that aligns with Thermo Fisher&#8217;s disciplined approach to portfolio management. With USD 645 million in 2025 revenue, the microbiology business represented approximately 2-3% of Thermo Fisher&#8217;s total revenue base, making it a logical candidate for divestiture as the company focuses on larger-scale opportunities.<\/p>\n\n\n\n<p>For Astorg, the acquisition provides a platform to build a standalone microbiology-focused company with established customer relationships across multiple attractive end markets. The business&#8217;s diversified revenue streams across clinical, pharmaceutical, and food safety applications provide resilience against market-specific downturns.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the transaction, regulatory approvals, and strategic implications. Actual outcomes may differ due to risks including regulatory decisions, closing conditions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1261,523],"class_list":["post-64126","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-nyse-tmo","tag-thermo-fisher-scientific"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately USD 1.075 billion in total consideration.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64126\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization\" \/>\n<meta property=\"og:description\" content=\"Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately USD 1.075 billion in total consideration.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64126\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T04:05:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T04:05:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64126#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64126\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization\",\"datePublished\":\"2026-04-28T04:05:24+00:00\",\"dateModified\":\"2026-04-28T04:05:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64126\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NYSE: TMO\",\"Thermo Fisher Scientific\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64126#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64126\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64126\",\"name\":\"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-28T04:05:24+00:00\",\"dateModified\":\"2026-04-28T04:05:25+00:00\",\"description\":\"Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately USD 1.075 billion in total consideration.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64126#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64126\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64126#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization - Insight, China&#039;s Pharmaceutical Industry","description":"Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately USD 1.075 billion in total consideration.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64126","og_locale":"en_US","og_type":"article","og_title":"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization","og_description":"Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately USD 1.075 billion in total consideration.","og_url":"https:\/\/flcube.com\/?p=64126","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T04:05:24+00:00","article_modified_time":"2026-04-28T04:05:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64126#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64126"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization","datePublished":"2026-04-28T04:05:24+00:00","dateModified":"2026-04-28T04:05:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64126"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NYSE: TMO","Thermo Fisher Scientific"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64126#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64126","url":"https:\/\/flcube.com\/?p=64126","name":"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-28T04:05:24+00:00","dateModified":"2026-04-28T04:05:25+00:00","description":"Thermo Fisher Scientific Inc. (NYSE: TMO) announced on April 27, 2026, that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately USD 1.075 billion in total consideration.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64126#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64126"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64126#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion \u2013 Strategic Portfolio Optimization"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64126"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64126\/revisions"}],"predecessor-version":[{"id":64127,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64126\/revisions\/64127"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}